Pimocard Plus is an advanced cardio-protective formulation designed for the effective management of congestive heart failure (CHF) in dogs caused by atrioventricular valvular insufficiency (AVVI) and mitral valve disease (MVD). Combining Pimobendan, Benazepril Hydrochloride, and Co-enzyme Q10, it provides synergistic benefits by enhancing heart function, reducing cardiac strain, and offering end-organ protection for the brain, liver, kidneys, and eyes. Its renoprotective properties make it suitable for chronic kidney disease (CKD) patients, ensuring overall cardiovascular support. With precise weight-based dosing, Pimocard Plus ensures optimal heart care for pets with heart conditions, improving their quality of life.
AVVI Management – For congestive heart failure due to atrioventricular valvular insufficiency (AVVI).
MVD Treatment – Use in Mitral Valve Disease (MVD) before CHF onset.
End-Organ Protection – Supports brain, liver, kidney, and eye health.
Synergistic Effect – More effective than monotherapy.
Renoprotection – Recommended for CKD patients.
0.2 to 0.6 mg/kg/Dog Or 0.5 mg/kg daily in conjunction with other cardiac drugs
20 - 30 kg = 1 × 5 mg Twice daily
10 - 20 kg = 1 × 2.5 mg Twice daily
30 - 40 kg = 2.5 × 5 mg Twice daily
40 - 60 kg = 2 × 5 mg Twice daily
Pimocard Plus is available in three dosage variations—1.25 mg, 2.5 mg, and 5 mg—to provide precise and tailored treatment for dogs of different sizes and severity of heart conditions. This ensures accurate dosing based on the pet’s weight and medical requirements, enhancing safety and effectiveness. By offering multiple strengths, it allows veterinarians to customize therapy for optimal cardiac support, preventing under- or overdosing. The combination of Pimobendan, Benazepril Hydrochloride, and Co-enzyme Q10 provides synergistic benefits by improving heart function, reducing strain on the heart, and protecting vital organs. This makes Pimocard Plus the best choice for managing congestive heart failure (CHF) and mitral valve disease (MVD) with precision and reliability.
Pimocard Plus combines Pimobendan, Benazepril Hydrochloride, and Co-enzyme Q10, offering a multifaceted approach to managing congestive heart failure (CHF) and mitral valve disease (MVD). Pimobendan enhances heart muscle contraction and reduces cardiac workload, Benazepril is an ACE inhibitor that lowers blood pressure and prevents further cardiac deterioration, and Co-enzyme Q10 provides antioxidant support, improving energy metabolism in heart cells.
Pimocard Plus is available in three dosage strengths (1.25 mg, 2.5 mg, and 5 mg) to ensure accurate, weight-based dosing for dogs of all sizes. This precise approach prevents over- or under-dosing, ensuring maximum efficacy with minimal side effects. The flexible dosage options allow for customized treatment, making it a trusted choice for long-term cardiac management.
Q
What is Pimocard used for?
A
Pimocard is used for the treatment of congestive heart failure (CHF) in dogs caused by Dilated Cardiomyopathy (DCM) or Atrioventricular Valvular Insufficiency (AVVI). It helps improve heart function and prolongs survival.
Q
How does Pimocard benefit dogs with heart disease?
A
Pimocard works by strengthening the heart muscle and widening blood vessels, allowing the heart to pump more efficiently. This reduces strain on the heart and improves blood circulation.
Q
Is Pimocard safe for long-term use?
A
Yes, Pimocard is safe for long-term use under veterinary supervision. Regular check-ups are recommended to monitor the dog's heart health and adjust the dosage if needed.